Search Results - "Rajkhowa, Trivikram"

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia by Maziarz, Richard T., Levis, Mark, Patnaik, Mrinal M., Scott, Bart L., Mohan, Sanjay R., Deol, Abhinav, Rowley, Scott D., Kim, Dennis D. H., Hernandez, Daniela, Rajkhowa, Trivikram, Haines, Kelly, Bonifacio, Gaetano, Rine, Patrice, Purkayastha, Das, Fernandez, Hugo F.

“…We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT)…”
Get full text

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML by Pratz, Keith W., Sato, Takashi, Murphy, Kathleen M., Stine, Adam, Rajkhowa, Trivikram, Levis, Mark

“…We examined 6 different FMS-like tyrosine kinase-3 (FLT3) inhibitors (lestaurtinib, midostaurin, AC220, KW-2449, sorafenib, and sunitinib) for potency against…”
Get full text

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia by Lee, Lauren, Hizukuri, Yoshiyuki, Severson, Paul, Powell, Benjamin, Zhang, Chao, Ma, Yan, Narahara, Maiko, Sumi, Hiroyuki, Hernandez, Daniela, Rajkhowa, Trivikram, Bollag, Gideon, Levis, Mark

“…Acute myeloid leukemia patients with FLT3-ITD mutations have a high risk of relapse and death. FLT3 tyrosine kinase inhibitors improve overall survival, but…”
Get full text

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia by Pratz, Keith W, Kaplan, Jason, Levy, Moshe, Bixby, Dale, Burke, Patrick W, Erba, Harry, Wise-Draper, Trisha M, Roboz, Gail J, Papadantonakis, Nikolaos, Rajkhowa, Trivikram, Hernandez, Daniela, Dobler, Iwona, Gregory, Richard C, Li, Cheryl, Wang, Shining, Stumpo, Kate, Kannan, Karuppiah, Miao, Harry, Levis, Mark

“…Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine…”
Get full text

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine by Karantanos, Theodoros, Teodorescu, Patric, Arvanitis, Marios, Perkins, Brandy, Jain, Tania, DeZern, Amy E, Dalton, W Brian, Christodoulou, Ilias, Paun, Bogdan C, Varadhan, Ravi, Esteb, Christopher, Rajkhowa, Trivikram, Bonifant, Challice, Gondek, Lukasz P, Levis, Mark J, Yegnasubramanian, Srinivasan, Ghiaur, Gabriel, Jones, Richard J

“…Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy…”
Get full text

A potential therapeutic target for FLT3-ITD AML: PIM1 kinase by Fathi, Amir T, Arowojolu, Omotayo, Swinnen, Ian, Sato, Takashi, Rajkhowa, Trivikram, Small, Donald, Marmsater, Fredrik, Robinson, John E, Gross, Stefan David, Martinson, Matthew, Allen, Shelley, Kallan, Nicholas C, Levis, Mark

“…Abstract Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) mutation have a poor prognosis, and FLT3 inhibitors are now…”
Get full text

The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia by Karantanos, Theodoros, Teodorescu, Patric, Perkins, Brandy, Christodoulou, Ilias, Esteb, Christopher, Varadhan, Ravi, Helmenstine, Eric, Rajkhowa, Trivikram, Paun, Bogdan C, Bonifant, Challice, Dalton, W Brian, Gondek, Lukasz P, Moliterno, Alison R, Levis, Mark J, Ghiaur, Gabriel, Jones, Richard J

“…The identification of new pathways supporting the myelodysplastic syndrome (MDS) primitive cells growth is required to develop targeted therapies. Within…”
Get full text

Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia by Chen, Yi-Bin, Li, Shuli, Lane, Andrew A, Connolly, Christine, Del Rio, Candice, Valles, Betsy, Curtis, Morgan, Ballen, Karen, Cutler, Corey, Dey, Bimalangshu R, El-Jawahri, Areej, Fathi, Amir T, Ho, Vincent T, Joyce, Amy, McAfee, Steven, Rudek, Michelle, Rajkhowa, Trivikram, Verselis, Sigitas, Antin, Joseph H, Spitzer, Thomas R, Levis, Mark, Soiffer, Robert

“…Abstract The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is associated with a high relapse rate for patients with acute myeloid…”
Get full text

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants by Galanis, Allison, Ma, Hayley, Rajkhowa, Trivikram, Ramachandran, Abhijit, Small, Donald, Cortes, Jorge, Levis, Mark

“…Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute myeloid leukemia patients and lead to constitutive activation. This…”
Get full text

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor by Lee, Lauren Y., Hernandez, Daniela, Rajkhowa, Trivikram, Smith, Samuel C., Raman, Jayant Ranganathan, Nguyen, Bao, Small, Donald, Levis, Mark

Get full text

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation by Ravandi, Farhad, Alattar, Mona Lisa, Grunwald, Michael R., Rudek, Michelle A., Rajkhowa, Trivikram, Richie, Mary Ann, Pierce, Sherry, Daver, Naval, Garcia-Manero, Guillermo, Faderl, Stefan, Nazha, Aziz, Konopleva, Marina, Borthakur, Gautam, Burger, Jan, Kadia, Tapan, Dellasala, Sara, Andreeff, Michael, Cortes, Jorge, Kantarjian, Hagop, Levis, Mark

“…Patients received 5-azacytidine (AZA) 75 mg/m2 intravenously daily for 7 days and sorafenib 400 mg orally twice daily continuously; cycles were repeated at…”
Get full text

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome by Strati, Paolo, Kantarjian, Hagop, Ravandi, Farhad, Nazha, Aziz, Borthakur, Gautam, Daver, Naval, Kadia, Tapan, Estrov, Zeev, Garcia‐Manero, Guillermo, Konopleva, Marina, Rajkhowa, Trivikram, Durand, Menda, Andreeff, Michael, Levis, Mark, Cortes, Jorge

“…We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome…”
Get full text

CCRL2 Promotes Cytokine-Regulated Growth of Erythroleukemia Cells by Karantanos, Theodoros, Esteb, Christopher, Teodorescu, Patric, Perkins, Brandy, Christodoulou, Ilias, Vorri, Stamatia, Rajkhowa, Trivikram, Dalton, William Brian, Ghiaur, Gabriel, Jones, Richard J.

Get full text

The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells by Chang, E, Ganguly, S, Rajkhowa, T, Gocke, C D, Levis, M, Konig, H

“…Effective treatment regimens for elderly acute myeloid leukemia (AML) patients harboring internal tandem duplication mutations in the FMS-like tyrosine…”
Get full text

Renal proximal tubule Na,K-ATPase is controlled by CREB-regulated transcriptional coactivators as well as salt-inducible kinase 1 by Taub, Mary, Garimella, Sudha, Kim, Dongwook, Rajkhowa, Trivikram, Cutuli, Facundo

“…Sodium reabsorption by the kidney is regulated by locally produced natriuretic and anti-natriuretic factors, including dopamine and norepinephrine,…”
Get full text

A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia by Levis, Mark, Perl, Alexander, Schiller, Gary, Fathi, Amir T., Roboz, Gail, Wang, Eunice S., Altman, Jessica, Rajkhowa, Trivikram, Ando, Makoto, Suzuki, Takeaki, Subach, Ruth Ann, Maier, Gary, Madden, Timothy, Johansen, Mary, Cheung, Kin, Kurman, Michael, Smith, Catherine

“…•FF-10101 is an irreversible inhibitor of FLT3 active against most types of FLT3 activating mutations.•FF-10101 induced responses in patients who had…”
Get full text

Abstract 3660: Crenolanib: A next generation FLT3 inhibitor by Galanis, Allison, Rajkhowa, Trivikram, Muralidhara, Chaitanya, Ramachandran, Abhijit, Levis, Mark

“…Every year in the US there are approximately 12,000 new cases of acute myeloid leukemia (AML). Amongst these patients, 25% have internal tandem duplications…”
Get full text

Regulation of renal proximal tubule Na-K-ATPase by prostaglandins by Herman, Maryann B, Rajkhowa, Trivikram, Cutuli, Facundo, Springate, James E, Taub, Mary

“…Prostaglandins (PGs) play a number of roles in the kidney, including regulation of salt and water reabsorption. In this report, evidence was obtained for…”
Get more information

Crenolanib Is A Highly Potent, Selective, FLT3 TKI with Activity Against D835 Mutations by Galanis, Allison, Rajkhowa, Trivikram, Muralidhara, Chaitanya, Ramachandran, Abhijit, Levis, Mark J.

“…Abstract 1341 Approximately 23% of acute myeloid leukemia (AML) patients have internal tandem duplications (ITD) of the type III receptor tyrosine kinase FLT3…”
Get full text

FLT3 Mutant to Wild Type Allelic Ratio and Clinical Status Are Predictive of Response to FLT3 Inhibitors in AML by Levis, Mark, Sato, Takashi, Murphy, Kathleen, Rajkhowa, Trivikram, Pratz, Keith

“…Abstract 1716 Poster Board I-742 AML patients who harbor FLT/ITD mutations have a poor prognosis. Several small molecule kinase inhibitors with activity…”
Get full text